Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Denali Therapeutics Inc. (DNLI)

Denali Therapeutics completes $195.0 million sale of priority review voucher

Positive Impact 4 of 5 m&a Written later

Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026, receiving gross proceeds of $195.0 million at closing. The voucher was received when the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026, and the sale was made under an asset purchase agreement dated June 12, 2026.

Key points

  • Gross proceeds of $195.0 million received from the buyer at closing on July 27, 2026
  • Voucher received when FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
  • Sale made under asset purchase agreement dated June 12, 2026; buyer not named in the filing
  • Full agreement to be filed as an exhibit to a later SEC filing

The filing

CompanyDenali Therapeutics Inc. (DNLI)
Form8-K, current report
Filed with the SECJul 27, 2026, 9:01 PM ET
Accession number0001714899-26-000086

Items reported: 2.01 Acquisition or Disposition Completed

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.